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Abstract
Aims/hypothesis Chronic exposure of pancreatic beta cells to
proinflammatory cytokines leads to impaired insulin secretion
and apoptosis. ARE/poly(U)-binding factor 1 (AUF1) belongs
to a protein family that controls mRNA stability and transla-
tion by associating with adenosine- and uridine-rich regions of
target messengers. We investigated the involvement of AUF1
in cytokine-induced beta cell dysfunction.
Methods Production and subcellular distribution of AUF1
isoforms were analysed by western blotting. To test for their
role in the control of beta cell functions, each isoform was
overproduced individually in insulin-secreting cells. The con-
tribution to cytokine-mediated beta cell dysfunction was eval-
uated by preventing the production of AUF1 isoforms by
RNA interference. The effect of AUF1 on the production of
potential targets was assessed by western blotting.
Results MIN6 cells and human pancreatic islets were found
to produce four AUF1 isoforms (p42>p45>p37>p40).
AUF1 isoforms were mainly localised in the nucleus but
were partially translocated to the cytoplasm upon exposure
of beta cells to cytokines and activation of the ERK pathway.
Overproduction of AUF1 did not affect glucose-induced
insulin secretion but promoted apoptosis. This effect was
associated with a decrease in the production of the anti-
apoptotic proteins, B cell leukaemia/lymphoma 2 (BCL2)
and myeloid cell leukaemia sequence 1 (MCL1). Silencing
of AUF1 isoforms restored the levels of the anti-apoptotic
proteins, attenuated the activation of the nuclear factor-κB
(NFκB) pathway, and protected the beta cells from cytokine-
induced apoptosis.
Conclusions/interpretation Our findings point to a contri-
bution of AUF1 to the deleterious effects of cytokines on
beta cell functions and suggest a role for this RNA-binding
protein in the early phases of type 1 diabetes.
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Introduction
Type 1 diabetes is an autoimmune disease characterised by a
progressive loss of pancreatic beta cells. Insulin, the hor-
mone produced by these cells, plays an essential role in the
maintenance of blood glucose homeostasis. During the auto-
immune attack, macrophages and lymphocytes infiltrate
pancreatic islets and release proinflammatory cytokines with
a major impact on the expression of key beta cell genes
leading to defective insulin secretion and sensitisation to
apoptosis [1, 2].
Most studies investigating the causes of beta cell dys-
function during the early phases of type 1 diabetes have
focused on the role of signalling cascades culminating in the
activation of transcription factors [1], but, so far, the poten-
tial impact of cytokines on mRNA stability has been poorly
investigated. Several RNA-binding proteins are known to
bind to specific sequences located on the 3′-untranslated
region (3′-UTR) of target mRNAs. A family of RNA-
binding proteins called AU-rich (ARE)-binding proteins
(AUBPs) interacts specifically with adenosine- and
uridine-rich regions located in the 3′-UTR of target mRNAs
[3]. Under resting conditions, AUBPs are principally located
in the nucleus [4] but, upon stimulation, translocate to the
cytoplasm and bind to their targets, leading to mRNA pro-
tection, stabilisation, degradation or inhibition of messenger
translation [5]. AUF1 (ARE/poly(U)-binding factor 1) [6],
also known as hnRNP-D (heterogeneous nuclear ribonu-
cleoprotein D), was originally identified as a protein that
binds and induces the destabilisation of the mRNAs encod-
ing c-myc and granulocyte–macrophage colony-stimulating
factor [7]. AUF1 was later reported to affect the stability of a
large variety of mRNAs involved in inflammation, cell
cycle control or apoptosis [8, 9]. Although the destabilising
function of AUF1 is well documented, some studies suggest
that the protein can also exert a positive effect on mRNA
stability [10].
Four different isoforms of AUF1 resulting from differential
splicing of exons 2 and 7 have been described: p37, p40, p42
and p45 [11]. The production of these isoforms varies be-
tween cell types and developmental stages and can be modi-
fied in response to different stimuli [12]. Moreover, AUF1
isoforms are subjected to post-translational modifications
that affect the activation state of the RNA-binding protein
in a cell-type and treatment-dependent manner [13, 14].
Since many proteins involved in stress and immune
responses or in cellular growth are encoded by mRNAs
containing ARE sequences, AUF1 is a good candidate for
mediating the alterations in gene expression underlying the
impairment in beta cell activities observed in the presence of
proinflammatory cytokines.
The aim of this study was to investigate the possible
involvement of AUF1 in cytokine-mediated beta cell dys-
function and in the development of type 1 diabetes. We
found that AUF1 is indeed activated upon exposure to
cytokines and contributes to beta cell apoptosis elicited by
these proinflammatory mediators.
Methods
Chemicals The extracellular regulated MAP kinase (ERK)
inhibitor, PD98059, was obtained from Calbiochem–
Novabiochem (San Diego, CA, USA). The c-Jun N-terminal
kinase (JNK) inhibitor, SP600125, was from Enzo Life
Sciences (Plymouth Meeting, PA, USA). IL-1β and the p38
mitogen-activated protein kinase (MAPK) inhibitor, SB
239063, were purchased from Sigma (Buchs, Switzerland).
Recombinant mouse IFNγ was obtained from R&D Systems
(Minneapolis, MN, USA), and TNFα fromAlexis Corporation
(Lausen, Switzerland). Hoechst 33342 was purchased from
Invitrogen (Carlsbad, CA, USA).
Culture and transfection of insulin-secreting cell lines and
human pancreatic islets The insulin-secreting cell line,
MIN6 clone B1 [15], was cultured at a density of 1.5×105
cells/cm2 in DMEM/Glutamax medium (Invitrogen)
supplemented with 15% FCS, 50 IU/ml penicillin, 50 μg/ml
streptomycin and 70 μmol/l β-mercaptoethanol. The insulin-
producing cell line, INS-1E [16], was cultured at the same
density as MIN6 cells in RPMI 1640 (Invitrogen) supple-
mented with 10% FCS, 50 IU/ml penicillin, 50 μg/ml
streptomycin, 1 mmol/l sodium pyruvate and 50 μmol/l
β-mercaptoethanol.
Transient transfections of MIN6 and INS-1E cells were
performed with Lipofectamine 2000 (Invitrogen) following
the instructions provided by the manufacturer. For a 24-well
plate, 60 pmol small interfering RNA (siRNA) duplexes and
0.8 μg plasmids were used.
Human pancreatic islets were provided by the Cell Isolation
and Transplantation Center at the University of Geneva,
School of Medicine, thanks to the Islets for Research distribu-
tion programme of the European Consortium for Islet Trans-
plantation (ECIT) sponsored by the Juvenile Diabetes
Research Foundation. The purity of islet preparations used
for this study ranged from 80% to 95%, and the samples
contained 51±7% (mean±SD) insulin-positive cells, as
revealed by immunofluorescence analysis using an antibody
against insulin (Linco Research, St Charles, MO, USA).
The islets were cultured in CMRL medium (Invitrogen)
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supplemented with 10% FCS, 100 IU/ml penicillin,
100 μg/ml streptomycin, 2 mmol/l L-glutamine and
250 μmol/l HEPES. Islet cell monolayers were prepared by
treating the islets for 7–9 min with trypsin (0.25 mg/ml)/
EDTA at 37°C. The trypsinisation was terminated by adding
serum-containing culture medium. The cells were seeded at a
density of 5.5×104 cells/cm2. Human islet cells were trans-
fected using the same conditions as used for MIN6 cells.
AUF1 overproduction and downregulation To experimen-
tally increase AUF1 levels, MIN6 cells were transiently
transfected with plasmids expressing enhanced green fluores-
cent protein (EGFP)-labelled constructs of each individual
AUF1 isoform [17]. Reduction of the level of the selected
isoforms was achieved using siRNA duplexes directed
against: exon 2, targeting p45 and p40 (siAUF1p45p40); exon
7, targeting p45 and p42 (siAUF1p45p42); and a sequence
astride exon 3 and 4, targeting all isoforms (siAUF1all). The
sequences were the following: siAUF1p45p40, 5′-ACU CCU
CCC CAC GAC ACA CTT-3′; siAUF1p45p42, 5′-UCA AGG
CUA UGG CAA CUA UTT-3′; and siAUF1all, 5′-AGA
AAG AUC UGA AGG ACU ATT-3′. An siRNA duplex
directed against green fluorescent protein (GFP; 5′-GAC
GUA AAC GGC CAC AAG UUC-3′), which has no effect
on pancreatic beta cell functions, was used as control.
Analysis of the expression of protein-coding genes Total
RNA extraction was performed with the RNeasy mini kit
(Qiagen, Hilden, Germany). Conventional quantitative RT-
PCR (qRT-PCR) was carried out as described previously
[18]. Real-time PCRs were performed on a Bio-Rad MyiQ
Single-Color Real-Time PCR Detection System (Bio-Rad
Laboratories, Hercules CA, USA). The list of primers can be
found in electronic supplementary material (ESM) Table 1.
Samples were tested in triplicate, and the results were nor-
malised using cDNA amplified with 18S primers in the
same samples.
Secretion assay For assessment of the secretory capacity,
MIN6 cells (2×105) plated in 24-well dishes were transient-
ly co-transfected with AUF1-overexpressing plasmids and
with a construct encoding the human growth hormone
(hGH) (pXGH5; Nichols Institute Diagnostics, San Juan
Capistrano, CA, USA). After 72 h, the cells were washed
and preincubated for 30min inKrebs buffer (127mmol/l NaCl,
4.7 mmol/l KCl, 1 mmol/l CaCl2, 1.2 mmol/l KH2PO4,
1.2 mmol/l MgSO4, 5 mmol/l NaHCO3, 0.1% BSA and
25 mmol/l HEPES, pH 7.4) containing 2 mmol/l glucose.
The medium was then discarded, and the cells were incu-
bated for 45 min in either the same buffer (basal condition)
or Krebs buffer containing 20 mmol/l glucose (stimulatory
condition). After collection of the supernatant fractions, the
cells were lysed in PBS containing 0.5% Triton X-100 to
evaluate total cellular hGH content. The amount of hGH in
the samples was assessed using an hGH ELISA kit (Roche
Diagnostics, Rotkreuz, Switzerland). The same was per-
formed for measurement of insulin secretion except that
the cells were not co-transfected with hGH and the cells
were lysed in ethanol/acid (75% ethanol, 1.5% HCl and
23.5% water) to evaluate total insulin content. The amount
of insulin in the samples was assessed using Insulin ELISA
(EIA) (SPI-bio, Montigny-le-Bretonneux, France).
Subcellular fractionation and protein extraction Subcellular
fractionation was performed as described by Li et al. [19].
Briefly, cells were lysed for 15 min on ice using a Triton X-
100 lysis buffer (50 mmol/l Tris/HCl, pH 7.5, 0.5% Triton
X-100, 137.5 mmol/l NaCl, 10% glycerol, 1 mmol/l
sodium vanadate, 50 mmol/l NaF, 10 mmol/l sodium pyro-
phosphate, 5 mmol/l EDTA and the Protease Inhibitors
Cocktail [Sigma, St Louis, MO, USA]). After a 15 min
centrifugation at 12,000 g, the supernatant fraction was
collected and stored as ‘cytoplasmic fraction’. The pellet
was washed and resuspended in Triton X-100 lysis buffer
containing 0.5% SDS. After sonication, the tube was centri-
fuged at 12,000 g for 15 min. The supernatant fraction
yielded the ‘nuclear fraction’. To obtain whole cell extracts,
the cells were directly scraped into SDS-containing lysis
buffer.
Western blots Protein extracts (25–50 μg) were separated on
polyacrylamide gels and transferred to poly(vinylidine fluo-
ride) membranes. The membranes were incubated overnight
at 4°C with primary antibodies. Immunoreactive bands were
visualised by chemiluminescence (Amersham Biosciences,
Piscataway, NJ, USA) after incubation with horseradish
peroxidase-coupled secondary antibodies for 1 h at room
temperature. The antibody against AUF1 (07-260) was pur-
chased from Upstate (Temecula, CA, USA). The antibodies
against myeloid cell leukaemia sequence 1 (MCL1 [sc-819])
and lamin B (sc-6216) were purchased from Santa-Cruz
Biotechnology (Santa-Cruz, CA, USA). The antibodies
against B cell leukaemia/lymphoma 2 (BCL2 [2870]), in-
hibitor of kappa B (IκBα; 4814) and phospho-IκBα (2859)
were purchased from Cell Signaling Technologies (Danvers,
MA, USA). The antibody against actin (MAB1501) was
from Chemicon International (Temecula, CA, USA). Finally,
the antibody against α-tubulin (T5168) was obtained from
Sigma (Buchs, Switzerland).
Apoptosis assay For the assessment of the apoptotic activity,
MIN6 cells (1×105) and human dissociated islet cells plated
in 24-well dishes were transiently transfected with plasmids
overexpressing AUF1 isoforms or with siRNAs reducing
their endogenous level. Apoptosis was assessed 2 days later
by staining the cells with Hoechst 33342 (Invitrogen) and
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scoring the cells displaying pyknotic nuclei. The experi-
ments were carried out blindly, and at least 800 cells per
condition were analysed.
Immunohistochemistry Transfected MIN6 cells were incu-
bated overnight at 4°C with primary antibody directed
against cleaved caspase 3 (9661; Cell Signaling). Immuno-
labelled proteins were visualised by incubating the cells for
1 h at room temperature with fluorescent secondary anti-
bodies (Invitrogen). Images were obtained by fluorescence
microscopy.
Statistical analysis Statistical differences were tested by
ANOVA. The experiments including more than two groups
were first analysed by ANOVA, and multiple comparisons
of the means were then carried out using the post hoc
Dunnett’s test, with a discriminating p value of 0.05.
Results
We first determined the production pattern of AUF1 iso-
forms in pancreatic beta cells. We found that the mouse
insulin-secreting cell line, MIN6, expresses all four AUF1
isoforms. The two larger isoforms, p45 and p42, are the
most abundant, while p40 and p37 are less abundantly
produced (Fig. 1a). A similar pattern was observed in human
pancreatic islets (Fig. 1b) and in the rat insulin-secreting cell
line, INS-1E (not shown). Exposure to IL-1β (10 ng/ml;
5000 U/ml) for 24 h, alone or with a mix of cytokines
including IL-1β (0.1 ng/ml; 50 U/ml), TNFα (10 ng/ml;
500 U/ml) and IFNγ (30 ng/ml; 50 U/ml), two conditions
that trigger beta cell apoptosis, affected neither the total
amount of AUF1 present in MIN6 cells nor the ratio between
isoforms (ESM Fig. 1a, b). Similar data were obtained with
human islets incubated in the presence of 10 ng/ml IL-1β
(ESM Fig. 1c).
We then analysed the subcellular localisation of AUF1
isoforms. As demonstrated by the distribution of specific
markers (tubulin and lamin B), our fractionation protocol
allows a clear separation between cytosolic and nuclear
compartments (Fig. 2a). We found that, under resting con-
ditions, the bulk of p45 and p37 is localised in the nucleus,
while p40 is detected mainly in the cytosolic fraction. p42 is
readily detectable in both fractions and represents the most
abundant isoform in the cytosol (ESM Fig. 2a, b). Although,
as indicated above, cytokines do not affect the total cellular
AUF1 content, exposure to these inflammatory mediators
led to redistribution of a fraction of the RNA-binding protein
between cellular compartments. Indeed, 24 h of treatment with
the cytokine mix increases AUF1 levels in the cytosolic
fraction and decreases those detectable in the nuclear fraction,
suggesting activation and translocation of the protein from the
nucleus to the cytoplasm (Fig. 2a, b, c). The redistribution of
AUF1 isoforms was prevented by a pharmacological inhib-
itor of the mitogen-activated protein kinase (MAPK), ERK
(Fig. 3a, b, c), but not by agents blocking the JNK or p38
kinase pathways (not shown).
To assess whether AUF1 activation contributes to
cytokine-mediated beta cell dysfunction, AUF1 isoforms
were either overproduced individually in MIN6 cells using
specific constructs or silenced by RNA interference. Each of
the EGFP-tagged AUF1 constructs was overproduced to
comparable levels, and taking into account a transfection
efficiency with plasmids of ∼30% (determined by scoring
EGFP-positive cells) led to an approximately twofold to
threefold increase in the cellular level of each individual
isoform (ESM Fig. 3). Exogenously produced AUF1 iso-
forms displayed a subcellular localisation comparable to the
endogenous proteins and were mainly localised in the nu-
cleus (ESM Fig. 3). Silencing of AUF1 isoforms was
achieved with siRNAs directed against different regions of
the transcripts. We used siRNAs directed against exon 2
(shared by isoforms p45 and p40), exon 7 (shared by p45
and p42) or a sequence astride exon 3 and 4 (present in all
isoforms) (Fig. 4a). The efficiency of each of the three
siRNAs was assessed by western blotting (Fig. 4b, c, d).
We first examined whether changes in the level of AUF1
alter the capacity of pancreatic beta cells to synthesise and
Fig. 1 Abundance of AUF1 isoforms in insulin-secreting cells. Total
extracts of MIN6 cells (a) or isolated human pancreatic islets (b) were
analysed by western blotting using an antibody recognising all AUF1
isoforms. The bands corresponding to each of the AUF1 isoforms were
quantified by densitometric scanning of the films. The relative abun-
dance of each isoform was calculated by dividing the intensity of each
band by the signal obtained from all AUF1 isoforms; the results shown
are the mean±SD of five (MIN6) or three (human islets) independent
experiments
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secrete insulin. Overproduction of each isoform indepen-
dently did not significantly affect proinsulin mRNA levels
(ESM Fig. 4a). Moreover, blocking the production of AUF1
isoforms using siRNAs was not sufficient to restore proin-
sulin production (ESM Fig. 4b) and insulin content (ESM
Fig. 4c) in MIN6 cells treated with IL-1β (10 ng/ml) for
24 h.
We then assessed whether AUF1 overproduction affects
the secretory properties of beta cells. Overproduction of
AUF1 isoforms did not influence insulin secretion under
basal (2 mmol/l glucose) or stimulated (20 mmol/l glucose)
conditions (ESM Fig. 5a). To verify that failure to detect
changes in insulin secretion is not caused by the relatively
low transfection efficiency, the cells were transiently co-
transfected with AUF1-overproducing constructs and with
an hGH-encoding plasmid. hGH is specifically targeted to
beta cell secretory granules and is co-released with insulin
[20], allowing selective monitoring of exocytosis from the
transfected cells. AUF1 overproduction affected neither basal
nor glucose-induced hGH release, confirming that the
RNA-binding protein does not regulate the production
of essential components of the beta cell secretory machinery
(ESM Fig. 5b).
Prolonged exposure of pancreatic beta cells to cytokines
sensitises them to apoptosis. We found that overproduction
of p40, p42 and p45 isoforms increases the apoptotic rate of
ΜΙΝ6 cells by more than two fold (Fig. 5a). In contrast, p37
had no significant effect on cell survival. Interestingly, the
siRNAs directed against AUF1 isoforms reduced caspase 3
activation elicited by cytokines (Fig. 5b) and partially pro-
tected the cells from apoptosis (Fig. 5c). We then tested
whether the siRNAs directed against AUF1 isoforms im-
prove survival of primary human beta cells in the presence
of cytokines. Transfection of human islet cells with siRNAs
directed against AUF1 led to a decrease of ∼75±7% of the
mRNA encoding the RNA-binding protein. As was the case
for MIN6 cells, blockade of AUF1 production protected
human dissociated islet cells from cytokine-induced apopto-
sis (Fig. 5d). Human islet preparations are not composed
exclusively of beta cells. However, taken together with the
results obtained with MIN6 cells, these findings indicate
that activation of AUF1 is part of the signalling cascades
leading to cytokine-mediated beta cell death.
Next, we attempted to determine the molecular mecha-
nisms underlying the effect of AUF1 on beta cell survival. It
has been previously demonstrated that AUF1 isoforms can
destabilise the mRNAs encoding the anti-apoptotic protein,
BCL2 [21]. Western blotting analysis revealed that overpro-
duction of p45 AUF1 results in a significant decrease in the
production of BCL2 (Fig. 6a, b). Overproduction of p40 and
Fig. 3 Subcellular redistribution of AUF1 isoforms can be prevented
by inhibitors of ERK. a MIN6 cells were incubated for 0, 6 and 24 h
with a mixture of cytokines (Cyt Mix) including IL-1β (0.1 ng/ml),
TNFα (10 ng/ml) and IFNγ (30 ng/ml) in the presence (+) or absence
(−) of a pharmacological inhibitor of ERK (ERKi; 100 μmol/l). Cyto-
solic fractions were then analysed by western blotting using antibodies
against AUF1 and actin. b, cMIN6 cells were incubated for 24 h in the
presence (black bars) or absence (white bars) of the cytokines indicated
in (a). The fraction of the two most abundant AUF1 isoforms, p45
(b) and p42 (c), present in the cytosol was quantified by densitometric
scanning of the films. The signal obtained in control cells in the
absence of the ERK inhibitor was set to 100%. The figure shows the
mean±SD from three independent experiments. Significantly different
from control, *p<0.05
Fig. 2 Impact of proinflammatory cytokines on the subcellular distri-
bution of AUF1 isoforms. a MIN6 cells were incubated for 24 h in the
presence or absence of a mixture of cytokines (Cyt Mix) including IL-
1β (0.1 ng/ml), TNFα (10 ng/ml) and IFNγ (30 ng/ml). Cytosolic and
nuclear fractions were prepared as described in the methods section
and analysed by western blotting using antibodies against AUF1 and
against cytosolic (tubulin) and nuclear (lamin B) markers. The figure
shows a representative experiment. Quantification of the subcellular
distribution of AUF1 isoforms in MIN6 cells incubated in the presence
(black bars) or absence (white bars) of proinflammatory cytokines in
the cytosolic (b) and in the nuclear compartment (c). The bands
corresponding to each AUF1 isoform were quantified by densitometric
scanning of the films from three independent experiments. Significantly
different from control, *p<0.05 (n03)
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p42 displayed a similar tendency, but, possibly because of
the relatively low transfection efficiency obtained with plas-
mids, this did not reach statistical significance. Transfection
of the cells with the siRNAs that reduce AUF1 production
(all of them block p45) restored BCL2 levels in IL-1β-
treated cells (Fig. 6c, d). This effect is potentially linked to
the increase in Bcl2 mRNA stability observed upon AUF1
silencing (ESM Fig. 6 top panel). These findings may
explain, at least in part, the protective effect of the siRNAs
on beta cell survival. Recently, MCL1, another anti-
apoptotic protein belonging to the BCL2 family, was shown
to be downregulated on prolonged exposure of beta cells to
proinflammatory cytokines and to be involved in pancreatic
beta cell apoptosis [22]. Interestingly, we found that trans-
fection of MIN6 cells with the siRNAs that diminish AUF1
production restore MCL1 levels in IL-1β-treated cells
(Fig. 6c, e). In contrast with BCL2, this effect was not
Fig. 5 Involvement of AUF1 isoforms in cytokine-mediated apopto-
sis. a MIN6 cells were transiently transfected with plasmids encoding
individual AUF1 isoforms. Two days later, the cells were stained with
Hoechst 33342, and the fraction of them displaying pyknotic nuclei
was scored. The figure shows the mean±SD from six independent
experiments. Cell death in cells transfected with an empty EGFP
plasmid (vector) was 4±2%. The value obtained under control con-
ditions (vector) in each experiment was set to 100%. Significantly
different from control conditions, *p<0.05 (n06). b MIN6 cells were
transfected with siGFP (Control) or the indicated AUF1 siRNAs. The
day after, the cells were incubated in the absence (white bar) or
presence (black bars) of a mixture of cytokines including IL-1β
(0.1 ng/ml), TNFα (10 ng/ml) and IFNγ (30 ng/ml). The cells were
then stained with an antibody specifically recognising the activated
form of caspase 3. Cell death in siGFP-transfected cells incubated in
the absence of cytokines was 3±2%. Significantly different from
siGFP-transfected cells incubated with cytokines (Control+), *p<0.05
(n04). c MIN6 cells transfected with siGFP or AUF1 siRNAs were
incubated with (black bars) or without (white bar) the mixture of
cytokines indicated above. The fraction of cells displaying pyknotic
nuclei was determined by Hoechst 33342 staining. Cell death in siGFP-
transfected cells incubated in the absence of cytokines was 3±2%.
Significantly different from siGFP-transfected cells incubated with
cytokines (Control+), *p<0.05 (n04). d Human pancreatic islet cells
were transfected with a siRNA against GFP (Control) or with the
indicated AUF1 siRNAs. The day after, the cells were incubated in
the presence (black bars) or absence of IL-1β (0.1 ng/ml), TNFα
(10 ng/ml) and IFNγ (30 ng/ml) for 24 h. The fraction of cells
undergoing apoptosis was estimated by scoring the cells displaying
pyknotic nuclei. Cell death in control cells was 5±2%. Significantly
different from siGFP-transfected cells incubated with cytokines
(Control +), *p<0.05 (n03)
Fig. 4 Silencing of AUF1 isoforms by RNA interference. a Schematic
representation of the structure of the four AUF1 isoforms and of the
position of the sequences recognised by the different siRNAs. b–d
Western blotting of total extracts of MIN6 cells transiently transfected
with the three different siRNAs. The figures show a representative
experiment. Ctrl, control. The fraction of each AUF1 isoform present
in MIN6 cells transfected with control oligonucleotides or with si(All)
(b), si(p45p40) (c) and si(p45p42) (d) was quantified by densitometric
scanning of the films. Mean±SD values from three to four independent
experiments are shown. Significantly different from control, *p<0.05.
AU, arbitrary units
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related to changes in mRNA stability (ESM Fig. 6 middle
panel).
Chronic activation of the nuclear factor-κB (NFκB) path-
way plays a central role in cytokine-mediated beta cell death
[23]. Since silencing of AUF1 prevents apoptosis triggered
by cytokines, we assessed whether reduction of the level of
the RNA-binding protein affects this important signalling
pathway.We discovered that phosphorylation of IκBα elicited
by a mix of cytokines, an essential step in the activation of the
NFκB pathway, is strongly impaired in cells in which AUF1
isoforms are downregulated (Fig. 7a, b). In contrast, phos-
phorylation of JNK, another signalling pathway playing a
central role in cytokine-mediated apoptosis, was unaffected
(data not shown).
Many of the deleterious effects triggered by chronic
NFκB activation in insulin-secreting cells result from the
induction of inducible nitric oxide synthase (iNOS) [24] and
of several chemokines [25] thought to elicit an inflammatory
cascade that promote the development of type 1 diabetes [1].
In agreement with the data described above, we found that
the induction of iNOS elicited by 6 h of IL-1β treatment is
significantly attenuated in MIN6 cells transfected with the
siRNAs against AUF1 (Fig. 8a). Moreover, the rise in two
chemokines containing an AUF1-binding motif in their
3′-UTR, chemokine (C-C motif) ligand 2/monocyte chemo-
tactic protein 1 (CCL2/MCP1) and chemokine (C-X-C motif)
ligand 2/macrophage inhibitor protein 2 (CXCL2/MIP2) [9],
elicited by proinflammatory cytokines was significantly di-
minished upon blockade of AUF1 production (Fig. 8b, c).
Taken together, these findings point to an important contri-
bution of AUF1 in NFκB-induced inflammatory reactions,
occurring in the initial phases of type 1 diabetes.
Discussion
The initial phases of type 1 diabetes are characterised by a
cytokine-mediated inflammatory reaction directed against pan-
creatic islets, which culminates in a progressive loss of beta
cells. Proinflammatory cytokines released by T lymphocytes
and macrophages invading the islets and by the endocrine cells
themselves alter beta cell gene expression by affecting the
activity of important transcription factors leading to impair-
ment of key signalling pathways. The involvement of trans-
cription factors such as NFκB, signal transducers and
activators of transcription 1 (STAT1) and activator protein 1
Fig. 6 Impact of AUF1 on the production of the anti-apoptotic pro-
teins BCL2 and MCL1. a MIN6 cells were transfected with an empty
plasmid (vector) or with plasmids driving the production of each of the
isoforms of AUF1. BCL2 and actin production were assessed by
western blotting. The figure shows a representative experiment out of
five. b Quantification of the impact of the overproduction of AUF1
isoforms on BCL2 production by densitometric scanning of the films.
The results are means±SD from five independent experiments. Signifi-
cantly different (*p<0.05) from the empty vector. c MIN6 cells were
transfected with a siRNA against GFP (Control) or with the indicated
AUF1 siRNAs. The day after, the cells were incubated for 24 h with
(+) or without (−) IL-1β (10 ng/ml). BCL2, MCL1 and actin produc-
tion were assessed by western blotting. Quantification of the impact of
AUF1 silencing on BCL2 (d) and MCL1 (e) production by densito-
metric scanning of the films. The results are means±SD from four
independent experiments. Significantly different from Control−
(†p<0.05) and from Control+ (*p<0.05)
Fig. 7 Silencing of AUF1 attenuates the induction of the NFκB
pathway elicited by cytokines. a MIN6 cells were transfected with a
siRNA against GFP (Control) or with the indicated AUF1 siRNAs. The
day after, the cells were incubated for 4 h with (+) or without (−) a mix
of cytokines (Cyt mix) including IL-1β (0.1 ng/ml), TNFα (10 ng/ml
and IFNγ (30 ng/ml). Phospho-IκBα (P-IκBα), IκBα and actin pro-
duction were assessed by western blotting. The figure shows a repre-
sentative experiment out of five. b Quantification of the impact of the
silencing of AUF1 during cytokine exposure on phospho-IκBα pro-
duction by densitometric scanning of the films. The results are
expressed as means±SD from five independent experiments
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(AP-1) in cytokine-mediated beta cell damage has been ex-
tensively investigated [26]. However, it is becoming increas-
ingly clear that other regulatory molecules, acting upstream
or downstream of transcription factors, make an important
contribution to the control of gene expression. This is the
case for RNA-binding proteins, such as AUF1, that bind to
specific regions of their target mRNAs, thereby influencing
their stability and translation. There is mounting evidence
that AUF1 plays a central role in inflammation. Indeed,
AUF1-binding motifs are present in the messengers of im-
portant inflammatory mediators such as the cytokines,
TNFα and granulocyte–macrophage colony-stimulating
factor [27, 28], the chemokines, CXCL2/MIP2 and CCL2/
MCP1 [9], and those of some interleukins [29, 30]. More-
over, AUF1 affects the production of important components
of the signalling pathways initiated by cytokines [31, 32].
Here, we demonstrate that beta cells produce four AUF1
isoforms that are differentially distributed between the cy-
tosolic and nuclear compartments. The localisation of AUF1
can be influenced by a variety of factors including: the
presence or absence of exons containing nuclear localisation
signals [33, 34]; interaction with transporters [35] or chap-
erones [36, 37]; protein ubiquitination [13]; and phosphor-
ylation of specific residues [7, 38]. At steady-state, most
AUF1 isoforms accumulate in the nucleus but are partially
relocalised upon exposure of insulin-secreting cells to proin-
flammatory cytokines. The precise mechanisms underlying
the nucleocytoplasmic shuttling of the protein have not yet
been defined. However, since the effect of the cytokines can
be prevented by inhibiting the MAPK, ERK, this process is
likely to involve the phosphorylation of one or more residues
of AUF1. In agreement with this hypothesis, nuclear ERK has
recently been reported to stimulate nucleocytoplasmic trans-
location and activation of AUF1p42 [39]. In contrast, in our
hands, neither JNK nor p38 MAPK appeared to affect the
localisation of AUF1 isoforms.
Prolonged exposure of beta cells to cytokines sensitises
them to apoptosis. Overproduction of p40, p42 and p45
AUF1 isoforms mimicked the effect of the cytokines and
led to a similar impact on beta cell survival. Moreover,
blockade of AUF1 production protected the beta cells from
apoptosis elicited by the cytokines, indicating that this
RNA-binding protein contributes to the deleterious events
that lead to death of insulin-secreting cells upon chronic
exposure to these inflammatory mediators. We were able
to partially elucidate the mechanisms through which AUF1
affects beta cell survival. Indeed, the reduction of the pro-
duction of two anti-apoptotic proteins, BCL2 and MCL1,
elicited by cytokines was efficiently prevented by silencing
AUF1. Both of these anti-apoptotic proteins have been
shown to play a role in beta cell survival [22, 40]. The effect
of AUF1 on BCL2 may be mediated, at least in part, by
direct association of the RNA-binding protein to the AU-rich
elements present in the 3′-UTR of Bcl2 mRNA, resulting in
messenger destabilisation [21, 41]. Indeed, we observed that
silencing of AUF1 results in a small but significant increase
in Bcl2 mRNA stability. So far, consensus sequences for
AUF1 binding have not been identified in the Mcl1 mRNA.
Moreover, blockade of AUF1 production by RNA interfer-
ence appears not to influence Mcl1 mRNA stability. Thus
the level of this anti-apoptotic protein is likely to be modu-
lated indirectly through the modification of other regulatory
factors.
Our results suggest that one of the key signalling pathways
involved in beta cell apoptosis is also regulated by AUF1. The
transcription factor NFκB contributes to cytokine-mediated
beta cell dysfunction and to the development of type 1
diabetes. Indeed, Eldor and collaborators showed that mice
Fig. 8 Silencing of AUF1 attenuates the induction of chemokines and
iNOS elicited by cytokines. a MIN6 cells were transfected with a
siRNA against GFP (Control) or with the indicated AUF1 siRNAs.
Two days later, the cells were treated with (black bars) or without
(white bar) IL-1β (10 ng/ml) for 6 h. The level of the iNos mRNAwas
determined by qRT-PCR. The values obtained for control cells incu-
bated in the presence of IL-1β was set to 100%. Significantly different
from control cells incubated with IL-1β, *p<0.05 (n04). b and c
MIN6 cells were transfected with a siRNA against GFP (Control) or
with the indicated AUF1 siRNAs. Two days later, the cells were treated
for 8 h with (black bars) or without (white bar) a mix of cytokines
including IL-1β (0.1 ng/ml), TNFα (10 ng/ml) and IFNγ (30 ng/ml).
The level of Ccl2/Mcp1 (b) and Cxcl2/Mip2 (c) mRNAs were deter-
mined by qRT-PCR. The values obtained for control cells were set to
100%. Significantly different from control cells incubated with cyto-
kines, *p<0.05 (n04–5)
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producing an NFκB repressor are protected from diabetes
induced by streptozotocin injections [42]. Recently, inhibi-
tion of AUF1 was reported to prevent lipopolysaccharide-
induced NFκB signalling in monocytes and macrophages
[43]. In agreement with these data, we found that phosphor-
ylation of IκBα elicited by a mix of cytokines, an essential
step in the activation of the NFκB pathway, is strongly
impaired in cells in which AUF1 isoforms are downregu-
lated. The attenuation of the NFκB signalling resulted in
reduced induction of iNOS and diminished production of
the chemokines, CXCL2/MIP2 and CCL2/MCP1. In other
cell types, AUF1 destabilises iNos mRNA [17]. Although
our data did not reach statistical significance, in MIN6 cells
treated with siRNAs directed against AUF1, iNos mRNA
tended to be more stable (ESM Fig. 6 bottom panel). There-
fore we cannot rule out the possibility that a similar mech-
anism also takes place in beta cells. However, even if
present, in MIN6 cells the effect on mRNA stability appears
to have less impact on iNOS levels than the attenuation of
the NFκB signalling. NO production plays a pivotal role in
the deleterious action exerted by proinflammatory cytokines
on beta cells [44]. Therefore, at least part of the protective
effect of AUF1 silencing can probably be attributed to the
smaller induction of iNOS. Chemokines such as CXCL2/
MIP2 and CCL2/MCP1 released by beta cells chronically
exposed to cytokines are thought to constitute an immuno-
genic signal that favours the recruitment of immune cells
and contributes to the amplification of the inflammatory
reaction [1]. Our findings indicate that activation of AUF1
can modulate this inflammatory signal that promotes the
development of type 1 diabetes.
In this study, we highlighted an important contribution of
AUF1 to the deleterious effects of proinflammatory cyto-
kines on beta cell survival. We were able to partially dissect
the events leading to AUF1 redistribution and to character-
ise the signalling cascades downstream of the activation of
the RNA-binding protein. Future studies need to precisely
identify the molecular mechanisms regulating the nucleocyto-
plasmic shuttling of AUF1 in cytokine-treated beta cells and to
definitively assess its contribution to the development of type 1
diabetes. Our findings suggest that a better knowledge of the
role played by AUF1 and other RNA-binding proteins in the
islet inflammatory reaction could potentially open the way to
new strategies to prevent beta cell death and the development of
type 1 diabetes.
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